Abstract
To the Editor.— In the October 1982 issue of Pediatrics is an advertisement by Bristol Laboratories concerning the use of Naldecon to improve the therapeutic outcome of otitis media with effusion. The advertisement states: "Naldecon improves therapeutic outcome in otitis media. A landmark study found that adjunctive administration of one antihistamine/decongestant liquid did more than relieve nasal symptoms. Naldecon actually improved the therapeutic outcome!" This statement appears to be in direct conflict with the study cited in the advertisement.1
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
